BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31829241)

  • 1. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study.
    Aitken CA; van Agt HME; Siebers AG; van Kemenade FJ; Niesters HGM; Melchers WJG; Vedder JEM; Schuurman R; van den Brule AJC; van der Linden HC; Hinrichs JWJ; Molijn A; Hoogduin KJ; van Hemel BM; de Kok IMCM
    BMC Med; 2019 Dec; 17(1):228. PubMed ID: 31829241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
    Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
    BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Melnikow J; Henderson JT; Burda BU; Senger CA; Durbin S; Weyrich MS
    JAMA; 2018 Aug; 320(7):687-705. PubMed ID: 30140883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing unnecessary referrals for colposcopy in hrHPV-positive women within the Dutch cervical cancer screening programme: A modelling study.
    Kaljouw S; Jansen EEL; Aitken CA; Harrijvan LM; Naber SK; de Kok IMCM
    Gynecol Oncol; 2021 Mar; 160(3):713-720. PubMed ID: 33451725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: a prospective cohort study.
    Loopik DL; Melchers W; Vedder J; van den Brule A; Massuger L; Bekkers R; Siebers AG
    BJOG; 2020 Dec; 127(13):1656-1663. PubMed ID: 32506627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of loss to follow-up in the Dutch organised HPV-based cervical cancer screening programme.
    Olthof EMG; Aitken CA; Siebers AG; van Kemenade FJ; de Kok IMCM
    Int J Cancer; 2024 Jun; 154(12):2132-2141. PubMed ID: 38436201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.
    Zhao Y; Bao H; Ma L; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wang HJ; Wu J
    BMC Med; 2021 Jul; 19(1):164. PubMed ID: 34261463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ideal strategy for cervical cancer screening in Japan: Result from the Fukui Cervical Cancer Screening Study.
    Kurokawa T; Onuma T; Shinagawa A; Chino Y; Kobayashi M; Yoshida Y
    Cytopathology; 2018 Aug; 29(4):361-367. PubMed ID: 29768678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of HPV-based cervical cancer screening in an organised regional screening programme: 3 years of experience.
    Veijalainen O; Kares S; Kujala P; Vuento R; Osuala V; Tirkkonen M; Luukkaala T; Kholová I; Mäenpää J
    Cytopathology; 2019 Mar; 30(2):150-156. PubMed ID: 30421573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cervical cancer screening with primary HPV-DNA test in the Local Health Authority 2 of Savona (Liguria Region, Northern Italy): a population-based study].
    Depetrini E; Bonelli L; Ardoino S; Cirucca MC; Contin R; De Leonardis D; Errigo V; Lugani A; Franco A; Pastorino A; Carrozzi G; Venturino E
    Epidemiol Prev; 2016; 40(3-4):171-8. PubMed ID: 27436250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The added value of digital imaging to reflex cytology for triage of high-risk human papillomavirus positive self-sampled material in cervical cancer screening: A prospective cohort study.
    Wiersma D; Vinke A; Siebers AG; Melchers WJG; Bekkers RLM; Loopik DL
    BJOG; 2023 Jan; 130(2):184-191. PubMed ID: 35993438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of high-risk HPV DNA genotyping for primary cervical cancer screening and triage of HPV-positive women, compared to cytology: preliminary results of the PIPAVIR study.
    Chatzistamatiou K; Moysiadis T; Angelis E; Kaufmann A; Skenderi A; Jansen-Duerr P; Lekka I; Kilintzis V; Angelidou S; Katsiki E; Hagemann I; Tsertanidou A; Koch I; Boecher O; Soutschek E; Maglaveras N; Agorastos T
    Arch Gynecol Obstet; 2017 May; 295(5):1247-1257. PubMed ID: 28337594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sociodemographic Characteristics and Screening Outcomes of Women Preferring Self-Sampling in the Dutch Cervical Cancer Screening Programme: A Population-Based Study.
    Aitken CA; Inturrisi F; Kaljouw S; Nieboer D; Siebers AG; Melchers WJG; van den Brule AJC; Molijn A; Hinrichs JWJ; Niesters HGM; van Kemenade FJ; Berkhof J; de Kok IMCM
    Cancer Epidemiol Biomarkers Prev; 2023 Feb; 32(2):183-192. PubMed ID: 36099416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-risk human papillomavirus detection in self-sampling compared to physician-taken smear in a responder population of the Dutch cervical screening: Results of the VERA study.
    Ketelaars PJW; Bosgraaf RP; Siebers AG; Massuger LFAG; van der Linden JC; Wauters CAP; Rahamat-Langendoen JC; van den Brule AJC; IntHout J; Melchers WJG; Bekkers RLM
    Prev Med; 2017 Aug; 101():96-101. PubMed ID: 28579497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing the feasibility of a rapid, high-volume cervical cancer screening programme using HPV self-sampling and digital colposcopy in rural regions of Yunnan, China.
    Goldstein A; Goldstein LS; Lipson R; Bedell S; Wang J; Stamper SA; Brenner G; Goldstein GR; O'Keefe KD; O'Keefe SC; O'Keefe M; O'Keefe T; Goldstein AR; Zhao A
    BMJ Open; 2020 Mar; 10(3):e035153. PubMed ID: 32234744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and Associated Factors of Abnormal Cervical Cytology and HighRisk HPV DNA among Bangkok Metropolitan Women.
    Tangjitgamol S; Kantathavorn N; Kittisiam T; Chaowawanit W; Phoolcharoen N; Manusirivithaya S; Khunnarong J; Srijaipracharoen S; Saeloo S; Krongthong W; Supawattanabodee B; Thavaramara T; Pataradool K
    Asian Pac J Cancer Prev; 2016; 17(7):3147-53. PubMed ID: 27509943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting.
    Kotaniemi-Talonen L; Nieminen P; Anttila A; Hakama M
    Br J Cancer; 2005 Oct; 93(8):862-7. PubMed ID: 16189520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resilience of the Dutch HPV-based cervical screening programme during the COVID-19 pandemic.
    Olthof EMG; Aitken CA; Siebers AG; van Kemenade FJ; de Kok IMCM
    Public Health; 2024 Feb; 227():42-48. PubMed ID: 38103276
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.